All In Biotech

Drug Trial Radar · NCT01207440

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

449

Actual

Start

Sep 30, 2010

Primary completion

Dec 20, 2018

Study completion Jan 17, 2019

Sponsor

Lead sponsor
Ariad PharmaceuticalsTakeda (TAK)
Sponsor type
Industry
First posted
Sep 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.

Conditions

  • Chronic Myeloid Leukemia
  • Ph+ Acute Lymphoblastic Leukemia

Interventions

  • PonatinibDrug

    Ponatinib tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR)Time frame: Up to 12 months after initiation of study treatment
  2. Percentage of AP-CML Participants With Major Hematologic Response (MaHR)Time frame: Up to 6 months after initiation of study treatment
  3. Percentage of BP-CML/Ph+ ALL Participants With MaHRTime frame: Up to 6 months after initiation of study treatment

Locations

42 sites in 11 countries. Site status is shown where the registry gives one.

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Alfred Hospital

    Box Hill, Victoria, Australia

  • Peter MacCallum Cancer Centre

    East Melbourne, Victoria, Australia

  • UCL Bruxelles

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Institut Bergonie

    Bordeaux, France

  • Hopital Andre Mignot

    Le Chesnay, France

  • Hopital Claude Huriez CHRU

    Lille, France

  • Chu Brabois

    Nancy, France

  • Hopital Archet

    Nice, France

  • Hopital St. Louis

    Paris, France

  • Hopital Edouard Herriot

    Pierre-Bénite, France

  • Entre Hospitalier Universitaire

    Poitiers, France

  • Hopital de Purpan

    Toulouse, France

  • Charite - Universitatsmedizin Berlin,

    Berlin, Germany

  • Klinikum der Goethe Universitat,

    Frankfurt, Germany

  • Universitatsklinikum Jena

    Jena, Germany

  • University of Heidelberg

    Mannheim, Germany

  • III. Med. Klinik und Poliklinik

    München, Germany

  • Universita di Bologna

    Bologna, Italy

  • University of Modena

    Modena, Italy

  • University of Milano Bicocca

    Monza, Italy

  • University of Turin

    Orbassano (TO), Italy

  • University Tor Vergata

    Roma, Italy

  • VU University Medical Center

    Amsterdam, Netherlands

  • University Medical Center Groeningen

    Groningen, Netherlands

  • Singapore General Hospital

    Singapore, Singapore

  • The Catholic University of Korea, Seoul St.Mary's Hospital

    Seoul, South Korea

  • Hospital Clinic

    Barcelona, Spain

  • La Paz

    Madrid, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital Clinico of Valencia

    Valencia, Spain

  • Lund University

    Lund, Sweden

  • Karolinska Hospital

    Stockholm, Sweden

  • University Hospital Uppsala

    Uppsala, Sweden

  • Gartnavel General Hospital

    Glasgow, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.